{
}
Roche has received EU approval for its Vabysmo prefilled syringe, targeting three retinal conditions that lead to blindness: wet age-related macular degeneration, diabetic macular oedema, and macular oedema following retinal vein occlusion. This ready-to-use formulation complements the existing vial option and aims to challenge Regeneron's Eylea, which currently dominates the market. With Vabysmo's sales surging 324% to $2.64bn, forecasts suggest it could reach $8.78bn by 2030, while Eylea's sales are expected to decline significantly.
Xaira Therapeutics has appointed former Roche executive Paulo Fontoura as its Chief Medical Officer, enhancing its leadership team amid a wave of retirements at companies like Alnylam and Regeneron. The billion-dollar AI-focused startup continues to expand its C-suite.
The convergence of science and technology is transforming healthcare, with Syfe's Healthcare Innovation portfolio offering diversified investment across genomics, biotechnology, pharmaceuticals, healthcare services, and medical devices. This portfolio includes six carefully selected ETFs, providing exposure to leading companies and innovations in the sector, while managing risks associated with long-term healthcare investments. With no minimum investment and low fees, it aims to capitalize on the future of healthcare advancements.
The global healthcare services market is projected to grow from $8,348.44 billion in 2023 to $8,963.64 billion in 2024, driven by advancements in medical technology, an aging population, and health insurance expansion. By 2028, it is expected to reach $10,908.99 billion, with key trends including telemedicine integration and patient-centered care. Shared medical appointments are gaining traction as a cost-effective model for managing chronic conditions, enhancing patient outcomes through collaborative care.
Regeneron Pharmaceuticals, Inc. has received a buy rating from UBS, highlighting its focus on developing treatments for eye diseases, inflammatory conditions, and cancer. The company's net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. As of the end of 2022, Regeneron boasts a clinical development portfolio of approximately 35 products.
Regeneron Pharmaceuticals, Inc. has received a buy rating from UBS, highlighting its focus on developing treatments for eye diseases, inflammatory conditions, and cancer. The company's net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. As of the end of 2022, Regeneron boasts a clinical development portfolio of approximately 35 products.
Regeneron Pharmaceuticals' shares dropped nearly 10% as third-quarter sales of Eylea fell short of expectations, raising concerns about future sales amid competition. In contrast, Madrigal Pharmaceuticals reported strong sales of its MASH drug, Rezdiffra, totaling $62 million, significantly exceeding forecasts. UCB's Alzheimer’s drug trial showed promising secondary results despite missing its main goal, while AbbVie announced a partnership with EvolveImmune Therapeutics to develop cancer therapies.
Alnylam Pharmaceuticals reported mixed Q3 earnings for the quarter ending September 30, 2024, with net product revenues rising to $420.1 million, up from $313.2 million the previous year. However, the company faced a net loss of $111.6 million, a decline from a net income of $147.8 million, primarily due to increased research and development expenses. Strategic collaborations with companies like Roche and Regeneron are expected to bolster future growth as Alnylam focuses on expanding its RNAi therapeutics pipeline.
Evommune, a California biotech startup, has secured $115 million in Series C funding to advance its immune drug candidates, EVO756 and EVO301, targeting chronic immune conditions. The funding will support three Phase 2 trials, with results expected by the end of 2026. EVO756, an oral treatment for chronic skin hives, aims to be a first-in-class therapy, while EVO301 targets atopic dermatitis and shows promise in early testing.
Woodline Partners, founded in 2018 by former Citadel managers, has achieved profitability every quarter and annual gains between 10.2% and 14.4%, even during market downturns. Managing nearly $8.5 billion, the firm employs a long-short strategy with a focus on health care and technology, while diversifying into other sectors. Its health care teams have consistently outperformed, contributing to the fund's resilience amid market volatility.
Regeneron Pharmaceuticals, Inc.
Companies
| Symbol | REGN |
| Name | Regeneron Pharmaceuticals, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | NY |
| City | Tarrytown |
| Zipcode | 10591-6707 |
| Website | http://www.regeneron.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Roche gains EU approval for Vabysmo prefilled syringe to challenge Eylea
13:19 13.12.2024
Xaira Therapeutics appoints former Roche executive as chief medical officer
13:00 13.12.2024
healthcare innovation portfolio targets advancements in pharmaceuticals and medical technologies
Masimo Corporation
Vertex Pharmaceuticals Incorporated
Abbott Laboratories
GE HealthCare Technologies Inc.
AtriCure, Inc.
Regeneron Pharmaceuticals, Inc.
Intuitive Surgical, Inc.
CRISPR Therapeutics AG
Veeva Systems Inc.
Johnson & Johnson
Cigna
Integra LifeSciences Holdings Corporation
CVS Health Corporation
Stryker Corporation
UnitedHealth Group Incorporated
Amgen Inc.
Penumbra, Inc.
Alphatec Holdings, Inc.
UCB SA
Boston Scientific Corporation
Eli Lilly and Company
USA
BEL
Beigene
Revolution Medicines
Gilead Sciences
Exelixis
Incyte
Show more
02:52 13.11.2024
global healthcare services market poised for significant growth through 2028
United States Dollar
Community Health Systems, Inc.
UnitedHealth Group Incorporated
CVS Health Corporation
Regeneron Pharmaceuticals, Inc.
Cardinal Health, Inc.
Fresenius Medical Care AG & Co. KGaA
Centene Corporation
Baxter International Inc.
Mayo Clinic
Agilent Technologies, Inc.
Johnson & Johnson
Pfizer Inc.
Cleveland Clinic Global Solutions LLC
McKesson Corporation
Merck & Co., Inc.
Abbott Laboratories
Bristol-Myers Squibb Company
Quest Diagnostics Incorporated
HCA Healthcare, Inc.
Gilead Sciences, Inc.
Kaiser Permanente Group Trust
Cigna Corporation
Stryker Corporation
Tenet Healthcare Corporation
Danaher Corporation
AbbVie Inc.
Boston Scientific Corporation
Molina Healthcare, Inc.
Align Technology, Inc.
AmerisourceBergen Corporation
Laboratory Corporation OF America Holdings
DaVita Inc.
Eli Lilly and Company
Humana Inc.
West Pharmaceutical Services, Inc.
Fresenius Medical Care AG & Co. KGaA
Kaiser Permanente
UnitedHealth Group Incorporated
Tenet Healthcare
HCA Healthcare
Show more
20:40 11.11.2024
regeneron pharmaceuticals receives buy rating as it expands drug portfolio
United States Dollar
Bayer AG
Sanofi
Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
DEU
FRA
USA
Roche
Bayer
Sanofi
Show more
16:08 01.11.2024
Regeneron Pharmaceuticals receives buy rating amid strong sales and collaborations
United States Dollar
Bayer AG
Sanofi
Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
DEU
FRA
USA
Roche
Bayer
Sanofi
Show more
16:08 01.11.2024
regeneron faces sales uncertainty while madrigal reports strong drug launch results
United States Dollar
Regeneron Pharmaceuticals, Inc.
H. Lundbeck A/S
AbbVie Inc.
PTC Therapeutics, Inc.
UCB SA
USA
Alistair Henry
David Risinger
Joseph Schwartz
Brian Abrahams
Show more
11:06 01.11.2024
Alnylam Pharmaceuticals reports mixed Q3 earnings amid rising product revenues
United States Dollar
Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
USA
Roche
Regeneron Pharmaceuticals
Show more
05:23 01.11.2024
Evommune secures 115 million dollars to advance immune drug development
United States Dollar
Regeneron Pharmaceuticals, Inc.
Incyte Corporation
Novartis AG
Celldex Therapeutics, Inc.
Sanofi
USA
Joe Biden
Luis Pena
Show more
16:05 31.10.2024
woodline partners achieves consistent profitability amid market volatility since inception
Regeneron Pharmaceuticals, Inc.
Eli Lilly and Company
Ovintiv Inc.
Mike Rockefeller
Matthew Hooker
Karl Kroeker
Show more
21:14 29.10.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Industry Trends
Global Trade Developments
Stock Market Updates
Industry Mergers & Acquisitions
Private Equity Deals
Government Economic Policies
Supply Chain Management
Fintech Startups
Venture Capital Investments
Retail and Consumer Goods
Inflation and Monetary Impact
Workplace Trends
Energy Sector Developments
Finance Mergers & Acquisitions
Central Bank Actions
CEO Changes
Emerging Startups
Crypto Policies and Governance
Countries:
Companies:
Apple Inc.
NIO Inc.
Nikkei 225
Google Inc.
Nintendo Co., Ltd.
Grab2Go AS
OLA ELECTRIC MOBILITY LTD
Eurasia Groupe SA
British International Investment plc
XPeng Inc.
Li Auto Inc.
Morgan Stanley
Taiwan Semiconductor Manufacturing Company Limited
VFS Global AG
LARGAN Precision Co.,Ltd
S&P/ASX 200
HANG SENG BANK
Delhivery Limited
Ecom Express Ltd.
Arazul Sequoia Capital FIM C Priv
Currencies:
United States Dollar
Indian Rupee
Euro
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
New Taiwan Dollar
Indonesian Rupiah
Saudi Riyal
Offshore Chinese Yuan
Hong Kong Dollar
Malaysian Ringgit
Filipino Peso
West African CFA Franc
South Korean Won
Thai Baht
Mexican Peso
Croatian Kuna
Bahraini Dinar
Egyptian Pound
People: